$22.10
2.30% yesterday
Nasdaq, Jun 11, 10:15 pm CET
ISIN
US92337R1014
Symbol
VERA
Sector
Industry

Vera Therapeutics Inc - Ordinary Shares - Class A Stock price

$22.10
-0.39 1.73% 1M
-24.36 52.43% 6M
-20.19 47.74% YTD
-16.33 42.49% 1Y
+10.60 92.17% 5Y
+10.60 92.17% 10Y
+21.28 2,595.12% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.52 2.30%
ISIN
US92337R1014
Symbol
VERA
Sector
Industry

Key metrics

Market capitalization $1.41b
Enterprise Value $870.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.63
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-193.25m
Free Cash Flow (TTM) Free Cash Flow $-156.41m
Cash position $589.83m
EPS (TTM) EPS $-2.75
P/E forward negative
Short interest 12.77%
Show more

Is Vera Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

Vera Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy
93%
Hold
7%

Financial data from Vera Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
92% 92%
-
- Research and Development Expense 144 144
89% 89%
-
-193 -193
-
-
- Depreciation and Amortization 0.19 0.19
-
-
EBIT (Operating Income) EBIT -193 -193
90% 90%
-
Net Profit -175 -175
86% 86%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vera Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vera Therapeutics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
3 days ago
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Indu...
Neutral
GlobeNewsWire
8 days ago
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Confe...
Neutral
GlobeNewsWire
9 days ago
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance...
More Vera Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marshall Fordyce
Employees 72
Founded 2016
Website veratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today